Clinical Trial Update: Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Herceptin for efficacy in HER2-negative breast cancer with circulating tumor cells.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | Status: COMPLETED